{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:59:32Z","timestamp":1791280772439,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T00:00:00Z","timestamp":1387238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T00:00:00Z","timestamp":1387238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1038\/leu.2013.375","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T07:33:04Z","timestamp":1387265584000},"page":"1299-1307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":261,"title":["Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders"],"prefix":"10.1038","volume":"28","author":[{"given":"M","family":"Ladetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Monitillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Drandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Barbero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Passera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ritgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"G\u00f6kbuget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Trautmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Faham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,17]]},"reference":[{"key":"BFleu2013375_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","volume":"48","author":"C Pott","year":"2011","unstructured":"Pott C . Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance. Semin Hematol 2011; 48: 172\u2013184.","journal-title":"Semin Hematol"},{"key":"BFleu2013375_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/hon.989","volume":"29","author":"S Ferrero","year":"2011","unstructured":"Ferrero S, Drandi D, Mantoan B, Ghione P, Omed\u00e8 P, Ladetto M . Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. Hematol Oncol 2011; 29: 167\u2013176.","journal-title":"Hematol Oncol"},{"key":"BFleu2013375_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.seminoncol.2011.11.009","volume":"39","author":"M Br\u00fcggemann","year":"2012","unstructured":"Br\u00fcggemann M, G\u00f6kbuget N, Kneba M . Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol 2012; 39: 47\u201357.","journal-title":"Semin Oncol"},{"key":"BFleu2013375_CR4","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1182\/blood-2012-06-379040","volume":"120","author":"M Br\u00fcggemann","year":"2012","unstructured":"Br\u00fcggemann M, Raff T, l Kneba M . Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012; 120: 4470\u20134481.","journal-title":"Blood"},{"key":"BFleu2013375_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/MOH.0b013e3283543d5c","volume":"19","author":"D Campana","year":"2012","unstructured":"Campana D . Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 2012; 19: 313\u2013318.","journal-title":"Curr Opin Hematol"},{"key":"BFleu2013375_CR6","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","volume":"115","author":"V Conter","year":"2010","unstructured":"Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Gr\u00fcmayer R, M\u00f6ricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206\u20133214.","journal-title":"Blood"},{"key":"BFleu2013375_CR7","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/blood-2009-11-253435","volume":"115","author":"P Stow","year":"2010","unstructured":"Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010; 115: 4657\u20134663.","journal-title":"Blood"},{"key":"BFleu2013375_CR8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","volume":"107","author":"M Br\u00fcggemann","year":"2006","unstructured":"Br\u00fcggemann M, Raff T, Flohr T, G\u00f6kbuget N, Nakao M, Droese J et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107: 1116\u20131123.","journal-title":"Blood"},{"key":"BFleu2013375_CR9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","volume":"109","author":"T Raff","year":"2007","unstructured":"Raff T, Kaiser M, G\u00f6kbuget N, L\u00fcschen S, Ritgen M, Trautmann H et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials. Blood 2007; 109: 910\u2013915.","journal-title":"Blood"},{"key":"BFleu2013375_CR10","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","volume":"113","author":"R Bassan","year":"2009","unstructured":"Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153\u20134162.","journal-title":"Blood"},{"key":"BFleu2013375_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.hoc.2009.07.010","volume":"23","author":"D Campana","year":"2009","unstructured":"Campana D . Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 1083\u20131098.","journal-title":"Hematol Oncol Clin North Am"},{"key":"BFleu2013375_CR12","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R et al. Adult patients with acute lymphoblastic leukemiaand molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012; 120: 1868\u20131876.","journal-title":"Blood"},{"key":"BFleu2013375_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2008.5","volume":"22","author":"T Flohr","year":"2008","unstructured":"Flohr T, Schrauder A, Cazzaniga G, Panzer-Gr\u00fcmayer R, van der Velden V, Fischer S et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771\u2013782.","journal-title":"Leukemia"},{"key":"BFleu2013375_CR14","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH, Beldjord K, B\u00f6ttcher S, Asnafi V et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010; 115: 3215\u20133223.","journal-title":"Blood"},{"key":"BFleu2013375_CR15","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"M Ladetto","year":"2008","unstructured":"Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Prospective, multicenter randomized GITMO\/IIL trial comparing in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004\u20134013.","journal-title":"Blood"},{"key":"BFleu2013375_CR16","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","volume":"28","author":"M Ladetto","year":"2010","unstructured":"Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077\u20132084.","journal-title":"J Clin Oncol"},{"key":"BFleu2013375_CR17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.bbmt.2007.05.012","volume":"13","author":"JR Brown","year":"2007","unstructured":"Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13: 1057\u20131065.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2013375_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","volume":"119","author":"B Paiva","year":"2012","unstructured":"Paiva B, Guti\u00e9rrez NC, Rosi\u00f1ol L, V\u00eddriales MB, Montalb\u00e1n M\u00c1, Mart\u00ednez-L\u00f3pez J et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687\u2013691.","journal-title":"Blood"},{"key":"BFleu2013375_CR19","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S B\u00f6ttcher","year":"2012","unstructured":"B\u00f6ttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980\u2013988.","journal-title":"J Clin Oncol"},{"key":"BFleu2013375_CR20","first-page":"175","volume-title":"Methods Mol Biol","author":"C Pott","year":"2013","unstructured":"Pott C, Br\u00fcggemann M, Ritgen M, van der Velden VH, van Dongen JJ, Kneba M . MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative. Methods Mol Biol Vol. 971. Humana press: Hertfordshire, UK, 2013; pp 175\u2013200."},{"key":"BFleu2013375_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/sj.leu.2404586","volume":"21","author":"VH van der Velden","year":"2007","unstructured":"van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604\u2013611.","journal-title":"Leukemia"},{"key":"BFleu2013375_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/sj.leu.2402206","volume":"15","author":"T Szczepa\u0144ski","year":"2001","unstructured":"Szczepa\u0144ski T, Willemse MJ, van Wering ER, van Weerden JF, Kamps WA, van Dongen JJ . Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 2001; 15: 1415\u20131423.","journal-title":"Leukemia"},{"key":"BFleu2013375_CR23","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1182\/blood-2012-05-429811","volume":"120","author":"C Gawad","year":"2012","unstructured":"Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood 2012; 120: 4407\u20134417.","journal-title":"Blood"},{"key":"BFleu2013375_CR24","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1182\/blood.V83.8.2238.2238","volume":"83","author":"A Beishuizen","year":"1994","unstructured":"Beishuizen A, Verhoeven MA, van Wering ER, Hahlen K, Hooijkaas H, van Dongen JJ . Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238\u20132247.","journal-title":"Blood"},{"key":"BFleu2013375_CR25","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1182\/blood.V99.7.2315","volume":"99","author":"T Szczepanski","year":"2002","unstructured":"Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJM . Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B -ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002; 99: 2315\u20132323.","journal-title":"Blood"},{"key":"BFleu2013375_CR26","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/leu.2013.52","volume":"27","author":"AC Logan","year":"2013","unstructured":"Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013; 27: 1659\u20131665.","journal-title":"Leukemia"},{"key":"BFleu2013375_CR27","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012; 120: 5173\u20135180.","journal-title":"Blood"},{"key":"BFleu2013375_CR28","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","volume":"17","author":"JJ van Dongen","year":"2003","unstructured":"van Dongen JJ, Langerak AW, Br\u00fcggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257\u20132317.","journal-title":"Leukemia"},{"key":"BFleu2013375_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1083-8791(00)70006-1","volume":"6","author":"M Ladetto","year":"2000","unstructured":"Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 241\u2013253.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2013375_CR30","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.leu.2401831","volume":"14","author":"M Br\u00fcggemann","year":"2000","unstructured":"Br\u00fcggemann M, Droese J, Bolz I, L\u00fcth P, Pott C, von Neuhoff N et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 2000; 14: 1419\u20131425.","journal-title":"Leukemia"},{"key":"BFleu2013375_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3324\/haematol.11267","volume":"93","author":"S B\u00f6ttcher","year":"2008","unstructured":"B\u00f6ttcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008; 93: 551\u2013559.","journal-title":"Haematologica"},{"key":"BFleu2013375_CR32","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/sj.leu.2401172","volume":"12","author":"C Pott","year":"1998","unstructured":"Pott C, Tiemann M, Linke B, Ott MM, von Hofen M, Bolz I et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 1998; 12: 1630\u20131637.","journal-title":"Leukemia"},{"key":"BFleu2013375_CR33","first-page":"1365","volume":"90","author":"ME Sarasquete","year":"2005","unstructured":"Sarasquete ME, Garc\u00eda-Sanz R, Gonz\u00e1lez D, Mart\u00ednez J, Mateo G, Mart\u00ednez P et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005; 90: 1365\u20131372.","journal-title":"Haematologica"},{"key":"BFleu2013375_CR34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/leu.2009.268","volume":"24","author":"M Br\u00fcggemann","year":"2010","unstructured":"Br\u00fcggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008. Leukemia 2010; 24: 521\u2013535.","journal-title":"Leukemia"},{"key":"BFleu2013375_CR35","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1200\/JCO.2008.21.3116","volume":"27","author":"NS Andersen","year":"2009","unstructured":"Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009; 27: 4365\u20134370.","journal-title":"J Clin Oncol"},{"key":"BFleu2013375_CR36","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687\u20132693.","journal-title":"Blood"},{"key":"BFleu2013375_CR37","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3324\/haematol.2011.052852","volume":"97","author":"S Ferrero","year":"2012","unstructured":"Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D et al. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica 2012; 97: 849\u2013853.","journal-title":"Haematologica"},{"key":"BFleu2013375_CR38","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1182\/blood-2011-03-343434","volume":"118","author":"A Hadzidimitriou","year":"2011","unstructured":"Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Pedersen LB et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011; 118: 3088\u20133095.","journal-title":"Blood"},{"key":"BFleu2013375_CR39","first-page":"781","volume":"91","author":"A Hadzidimitriou","year":"2006","unstructured":"Hadzidimitriou A, Stamatopoulos K, Belessi C, Lalayianni C, Stavroyianni N, Smilevska T et al. Immunoglobulin genes in multiple myeloma: expressedand non-expressed repertoires, heavy and light chainpairings and somatic mutation patterns in a series of 101 cases. Haematologica 2006; 91: 781\u2013787.","journal-title":"Haematologica"},{"key":"BFleu2013375_CR40","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2004.10.054","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460\u20131468.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2013375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013375","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:14:42Z","timestamp":1648743282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2013375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,17]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["BFleu2013375"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.375","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,17]]},"assertion":[{"value":"15 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FP, JZ, VC, MF are employees and stock holders at Sequenta Inc. Other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}